PE43795A1 - Compuesto neuroprotector - Google Patents

Compuesto neuroprotector

Info

Publication number
PE43795A1
PE43795A1 PE1995259688A PE25968895A PE43795A1 PE 43795 A1 PE43795 A1 PE 43795A1 PE 1995259688 A PE1995259688 A PE 1995259688A PE 25968895 A PE25968895 A PE 25968895A PE 43795 A1 PE43795 A1 PE 43795A1
Authority
PE
Peru
Prior art keywords
pct
sec
neuroprotector
compound
date
Prior art date
Application number
PE1995259688A
Other languages
English (en)
Inventor
Bertrand L Chenard
Todd W Butler
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE43795A1 publication Critical patent/PE43795A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE AL COMPUESTO 3R 4S 3-(4-(4-FLUOROFENIL)-4-HIDROXI-PIPERIDIN-1-IL)-CROMAN-4,7-DIOL, DE FORMULA I, SUS ISOMEROS OPTICOS EN FORMA DE UNA MEZCLA RACEMICA Y SUS ENANTIOMEROS DEXTROGIRATORIOS O LEVOGIRATORIOS EN FORMA INDEPENDIENTE, ASI COMO SUS SALES TAL COMO TARTRATO ETANOLATO HIDRATADO; EL CUAL ES UTIL COMO ANTAGONISTA DE AMINOACIDOS EXCITATORIOS, POR BLOQUEO DEL RECEPTOR AL INTERACTUAR CON EL SITIO DE UNION PARA EL GLUTAMATO, TAL COMO SOBRE EL RECEPTOR IONOTROPICO NMDA (N-METIL-D-ASPARTICO); POR LO QUE PUEDE SER UTIL EN EL TRATAMIENTO DE DESORDENES NEUROLOGICOS, CONVULSIVOS, ANSIOLITICOS, PSICOTICOS, Y EN EL TRATAMIENTO DE MIGRANA Y COMO RELAJANTE MUSCULAR
PE1995259688A 1994-01-31 1995-01-18 Compuesto neuroprotector PE43795A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US18947994A 1994-01-31 1994-01-31

Publications (1)

Publication Number Publication Date
PE43795A1 true PE43795A1 (es) 1995-12-09

Family

ID=22697514

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1995259688A PE43795A1 (es) 1994-01-31 1995-01-18 Compuesto neuroprotector

Country Status (27)

Country Link
US (1) US5744483A (es)
EP (1) EP0741724B1 (es)
JP (1) JP2866743B2 (es)
CN (1) CN1048247C (es)
AT (1) ATE183184T1 (es)
AU (1) AU684568B2 (es)
BR (2) BR9408506A (es)
CA (1) CA2182101C (es)
CO (1) CO4230161A1 (es)
CZ (1) CZ286757B6 (es)
DE (1) DE69420053T2 (es)
DK (1) DK0741724T3 (es)
EG (1) EG20672A (es)
ES (1) ES2134361T3 (es)
FI (1) FI113769B (es)
GR (1) GR3031356T3 (es)
HU (1) HU221633B1 (es)
IL (1) IL112415A (es)
MY (1) MY111623A (es)
NO (1) NO309190B1 (es)
NZ (1) NZ275151A (es)
PE (1) PE43795A1 (es)
PL (1) PL179448B1 (es)
RU (1) RU2126404C1 (es)
TW (1) TW449591B (es)
WO (1) WO1995020587A1 (es)
ZA (1) ZA95692B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010240A1 (en) * 1995-09-15 1997-03-20 Pfizer Inc. Phenol derivatives with pharmaceutical activity
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
ZA200108038B (en) * 2000-10-02 2003-04-01 Pfizer Prod Inc Prophylactic use of n-methyl-d-asparrate (NMDA) antagonists.
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
CA2547283C (en) * 2003-11-26 2010-11-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
RU2008115032A (ru) 2005-11-03 2009-12-10 Ф. Хоффманн-Ля Рош Аг (Ch) Арилсульфонилхроманы в качестве ингибиторов 5-нт6
KR20080095885A (ko) * 2006-01-20 2008-10-29 쉐링 코포레이션 벤젠설포닐-크로만, 티오크로만, 테트라하이드로나프탈렌 및 관련된 감마 세크라타제 억제제
EP2522647B1 (en) * 2011-05-10 2014-04-30 DSM IP Assets B.V. Process of separating chiral isomers of chroman compounds and their derivatives and precursors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3294804A (en) * 1961-01-27 1966-12-27 Sterling Drug Inc 1-(3-hydroxy-3-phenylpropyl)-4-phenyl-4-propionoxy-piperidine
FR5733M (es) * 1966-09-27 1968-01-22
GB1495526A (en) * 1974-05-31 1977-12-21 Beecham Group Ltd Chroman derivatives
US4016281A (en) * 1975-02-22 1977-04-05 Merck Patent Gesellschaft Mit Beschrankter Haftung Tetralone and indanone compounds
US4082755A (en) * 1977-02-14 1978-04-04 Janssen Pharmaceutica N.V. 1-[(Diarylmethyl)aminoalkyl]piperidimes
WO1980000152A1 (en) * 1978-07-03 1980-02-07 Sandoz Ag 3-aminopropoxy-aryl derivates,preparation and use thereof
US4358456A (en) * 1980-05-03 1982-11-09 John Wyeth & Brother Limited Antipsychotic piperidinomethyl-indole derivatives
DE3045688A1 (de) * 1980-12-04 1982-07-08 C.H. Boehringer Sohn, 6507 Ingelheim Neue 8-arylalkyl-3-phenyl-3-nortropanole, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3274350D1 (en) * 1981-09-25 1987-01-08 Beecham Group Plc Pharmaceutically active benzopyran compounds
EP0093534A1 (en) * 1982-04-28 1983-11-09 Beecham Group Plc Novel chromanols
GB8308064D0 (en) * 1983-03-24 1983-05-05 Beecham Group Plc Active compounds
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
US4957928A (en) * 1986-06-26 1990-09-18 Ciba-Geigy Corporation Hydrogenated 1-benzooxacycloalkylpyridinecarboxylic acid compounds
US4968678A (en) * 1988-02-19 1990-11-06 Eli Lilly And Company Tetrazole excitatory amino acid receptor antagonists
FR2640266B2 (fr) * 1988-07-12 1992-07-10 Synthelabo Derives de (hydroxy-1 piperidinyl-2 alkyl) indolones-2, quinoleinones-2, benzo(b)azepinones-2 et benzimidazolones-2, leur preparation et leur application en therapeutique
US4968878A (en) * 1989-02-07 1990-11-06 Transitions Research Corporation Dual bumper-light curtain obstacle detection sensor
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1990014087A1 (en) * 1989-05-17 1990-11-29 Pfizer Inc. 2-piperidino-1-alkanol derivatives as antiischemic agents
HU222726B1 (hu) * 1990-02-06 2003-09-29 Pfizer, Inc., Piperidinszármazékok, eljárás elżállításukra és az ezeket tartalmazó gyógyszerkészítmények
US5192751A (en) * 1992-07-24 1993-03-09 Eli Lilly And Company Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence

Also Published As

Publication number Publication date
JP2866743B2 (ja) 1999-03-08
CZ225696A3 (en) 1997-01-15
GR3031356T3 (en) 2000-01-31
BR9500380A (pt) 1995-10-17
BR9408506A (pt) 1997-08-05
ZA95692B (en) 1996-07-30
PL179448B1 (pl) 2000-09-29
NO963186D0 (no) 1996-07-30
IL112415A (en) 1999-07-14
FI950403A0 (fi) 1995-01-30
MY111623A (en) 2000-09-27
DE69420053D1 (de) 1999-09-16
CA2182101A1 (en) 1995-08-03
CA2182101C (en) 1999-08-03
NZ275151A (en) 1998-02-26
HUT75942A (en) 1997-05-28
DE69420053T2 (de) 1999-11-25
FI950403A (fi) 1995-08-01
FI113769B (fi) 2004-06-15
CO4230161A1 (es) 1995-10-19
CN1048247C (zh) 2000-01-12
EP0741724A1 (en) 1996-11-13
HU221633B1 (hu) 2002-12-28
HU9602100D0 (en) 1996-09-30
ES2134361T3 (es) 1999-10-01
CZ286757B6 (en) 2000-06-14
JPH09501698A (ja) 1997-02-18
CN1142825A (zh) 1997-02-12
PL315681A1 (en) 1996-11-25
TW449591B (en) 2001-08-11
WO1995020587A1 (en) 1995-08-03
ATE183184T1 (de) 1999-08-15
AU684568B2 (en) 1997-12-18
NO309190B1 (no) 2000-12-27
NO963186L (no) 1996-07-30
EG20672A (en) 1999-11-30
US5744483A (en) 1998-04-28
IL112415A0 (en) 1995-03-30
EP0741724B1 (en) 1999-08-11
RU2126404C1 (ru) 1999-02-20
AU8066394A (en) 1995-08-15
DK0741724T3 (da) 1999-12-20

Similar Documents

Publication Publication Date Title
UA49869C2 (uk) Нафтил-заміщені похідні бензимідазолу, фармацевтична композиція, спосіб лікування (варіанти) та спосіб інгібування людського фактора
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DK0946162T3 (da) Anvendelse af p-aminophenol-derivater til fremstilling af farmaceutiske præparater, som er nyttige til behandlingen af neurodegenerative sygdomme
PE43795A1 (es) Compuesto neuroprotector
RU94044356A (ru) Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с
NO20091111L (no) Anvendelse av R(+)-alfa-(2,3-dimetoksyfenyl)-l-[2-(4-fluorfenyl)etyl]-4-piperidin-metanol for behandling av sovnforstyrrelser
ES2105643T3 (es) Uso de la 2-(4-(4-clorofenil)ciclohexil)-3-hidroxi-1,4-naftoquinona para el tratamiento del cancer.
RU94044487A (ru) Применение 2-фенил-3-ароилбензотиофенов для лечения мужского бесплодия

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed